Cannabis and Cannabinoids in Cancer Therapy: 2025 Update

The use of cannabis and cannabinoids in cancer therapy is an evolving field with ongoing research exploring their potential benefits. This guide provides an overview of the current evidence as of July 10, 2025.

According to www.iAsk.Ai - Ask AI:

CBD (Cannabidiol):

CBD, a non-psychoactive compound found in cannabis, is known for its anti-inflammatory properties and its potential to limit cancer cell proliferation. Current research includes 2025 trials investigating its use in conjunction with chemotherapy for various cancers, including glioblastoma, breast cancer, and colon cancer.[1]

THC (Tetrahydrocannabinol):

THC, the primary psychoactive component of cannabis, has received FDA approval for managing nausea, appetite loss, and pain in cancer patients. Early data from research models suggests that THC may also have anti-tumor effects in certain cancers, such as prostate, breast, and glioblastoma.[1]

Rick Simpson Oil (RSO):

RSO is a high-THC cannabis extract that has gained anecdotal use in cancer treatment. As of 2025, lab trials are underway to investigate its effects in models of prostate and pancreatic cancer.[1]

CBG (Cannabigerol):

CBG shows promise in preclinical models, demonstrating neuroprotective effects and potential synergistic anti-cancer activity when combined with CBD and THC.[1]

The 2025 update indicates that CBD is being explored in trials alongside chemotherapy for glioblastoma, breast, and colon cancers. THC is FDA-approved for managing symptoms in cancer patients and shows early anti-tumor effects. RSO is under investigation in lab trials, and CBG shows potential synergistic effects with other cannabinoids.